Status:
UNKNOWN
NGAL and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial Infarction
Lead Sponsor:
Sheba Medical Center
Collaborating Sponsors:
Zotal Inc.
Conditions:
No-Reflow Phenomenon
STEMI - ST Elevation Myocardial Infarction
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study is to investigate the association between NGAL plasma levels in ST-elevation myocardial infarction and the no-reflow phenomenon, adverse events during hospitalization and at 30-d...
Detailed Description
Neutrophil Gelatinase-associated Lipocalin (NGAL) is a acute phase protein which is elevated in conditions like acute kidney injury and myocardial infarction. When a coronary artery is occluded, detri...
Eligibility Criteria
Inclusion
- Patients \> 18 years old presenting with ST-elevation myocardial infarction and undergoing urgent coronary angiography with or without PCI.
- Signed informed consent to participate in the study.
Exclusion
- Inability to sign written informed consent.
- Chronic renal failure (eGFR \< 30 ml/min/1.73m2).
Key Trial Info
Start Date :
September 15 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 31 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03264859
Start Date
September 15 2017
End Date
October 31 2018
Last Update
August 29 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Center, Cardiac Intensive Care Unit
Ramat Gan, Israel